Prevalence and Severity of Pruritus and Quality of Life in Patients With Cutaneous T-Cell Lymphoma

被引:70
|
作者
Wright, Abigail [1 ]
Wijeratne, Aruni [1 ]
Hung, Tracy [1 ]
Gao, Wei [2 ]
Whittaker, Sean [1 ,2 ]
Morris, Steven [1 ]
Scarisbrick, Julia [1 ]
Beynon, Teresa [1 ]
机构
[1] St Thomas Hosp, London SE1 7EH, England
[2] Kings Coll London, Kings Hlth Partners, London WC2R 2LS, England
关键词
Pruritus; itch; cutaneous T-cell lymphoma; CTCL; Skindex-29; quality of life; palliative care; MYCOSIS-FUNGOIDES; INTERNATIONAL-SOCIETY; PROGNOSTIC-FACTORS; SEZARY-SYNDROME; ORGANIZATION; SURVIVAL; PROPOSAL; OUTCOMES;
D O I
10.1016/j.jpainsymman.2012.01.012
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. Cutaneous T-cell lymphoma (CTCL), although rare, is associated with a significant symptom burden. Pruritus appears to be one of the most prominent and disturbing symptoms. Objectives. To describe the prevalence and severity of pruritus and quality of life (QOL) in patients with CTCL. Methods. Patients with CTCL able to complete two questionnaires were invited to complete a visual analogue scale for itch (VAS(itch)) and the Skindex-29. Prevalence of pruritus, mean score, and SD were estimated for the VAS(itch) and Skindex-29, and the Pearson's correlation coefficient was calculated to evaluate the relationship between severity of pruritus and QOL. Results. One hundred patients were recruited (mean [SD] age 57.9 [12.9] years, range 30-86 years). Eighty-eight percent reported pruritus in the preceding four weeks, 46% indicating that it was often or always a problem. The mean (SD) of VAS(itch) (n = 92) was 3.2 (3.2), range zero to 10. The mean (SD) total Skindex-29 score was 43.3 (27.7). More advanced disease stage was associated with poorer QOL. The Skindex-29 correlated strongly with the VAS(itch) (Pearson's correlation coefficient = 0.72, P < 0.001). Conclusion. All aspects of QOL are affected in CTCL. Pruritus is a common and troublesome symptom. A more advanced disease stage and more severe pruritus symptoms were associated with poorer QOL in this study. J Pain Symptom Manage 2013;45:114-119. (C) 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:114 / 119
页数:6
相关论文
共 50 条
  • [31] Cutaneous T-cell lymphoma
    Kotz, EA
    Anderson, D
    Thierst, BH
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2003, 17 (02) : 131 - 137
  • [32] Menus for Managing Patients With Cutaneous T-Cell Lymphoma
    Poligone, Brian
    Heald, Peter
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2012, 31 (01) : 25 - 32
  • [33] Forodesine in the treatment of cutaneous T-cell lymphoma
    Lewis, Daniel J.
    Duvic, Madeleine
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (06) : 771 - 775
  • [34] Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma
    Goyal, Amrita
    Foss, Francine
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (1-2) : 41 - 58
  • [35] CAUSES OF DEATH IN CUTANEOUS T-CELL LYMPHOMA PATIENTS
    Lebas, Eve
    Collins, Patrick
    Somja, Joan
    Nikkels, Arjen
    DERMATOLOGY, 2023, 239 (06) : 860 - 867
  • [36] MicroRNA Signatures in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma
    Shen, Xiaoyan
    Wang, Bo
    Li, Kejia
    Wang, Lili
    Zhao, Xiaoqing
    Xue, Feng
    Shi, Ruofei
    Zheng, Jie
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (09) : 2024 - 2032
  • [37] Immunobiology and treatment of cutaneous T-cell lymphoma
    Goel, Rishi R.
    Rook, Alain H.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (08) : 985 - 996
  • [38] Health-related quality of life in patients with cutaneous T-cell lymphoma?
    Holahan, Heather M.
    Farah, Ronda S.
    Fitz, Sara
    Mott, Sarah L.
    Ferguson, Nkanyezi N.
    McKillip, Julie
    Link, Brian
    Liu, Vincent
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (11) : 1314 - 1319
  • [39] Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases
    Poligone, Brian
    Rubio-Gonzalez, Belen
    Querfeld, Christiane
    DERMATOLOGIC THERAPY, 2019, 32 (02)
  • [40] Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma
    Hirai, Yoji
    Sakurai, Jun
    Yoshida, Shiho
    Kikuchi, Takashi
    Mitsuhashi, Toshiharu
    Miyake, Tomoko
    Fujimura, Taku
    Abe, Riichiro
    Fujikawa, Hiroki
    Boki, Hikari
    Suga, Hiraku
    Shibata, Sayaka
    Miyagaki, Tomomitsu
    Shimauchi, Takatoshi
    Kiyohara, Eiji
    Kawakami, Yoshio
    Morizane, Shin
    JOURNAL OF DERMATOLOGY, 2024, 51 (08) : 1037 - 1049